Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $46.43

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $46.43.

Several research firms have recently issued reports on OTLK. BTIG Research raised shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research report on Friday, May 17th.

Institutional Trading of Outlook Therapeutics

A hedge fund recently raised its stake in Outlook Therapeutics stock. Scotia Capital Inc. grew its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 420.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 338,439 shares of the company’s stock after purchasing an additional 273,463 shares during the quarter. Scotia Capital Inc. owned about 0.13% of Outlook Therapeutics worth $75,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 11.20% of the stock is owned by hedge funds and other institutional investors.

Outlook Therapeutics Stock Down 0.1 %

Shares of OTLK stock opened at $7.08 on Thursday. The firm has a market capitalization of $165.74 million, a P/E ratio of -0.62 and a beta of 0.71. Outlook Therapeutics has a twelve month low of $4.00 and a twelve month high of $37.00. The stock’s fifty day simple moving average is $7.64 and its 200 day simple moving average is $8.08.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.67). As a group, equities research analysts expect that Outlook Therapeutics will post -4.08 EPS for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.